Security
Scinai Immunotherapeutics Ltd. American Depositary Shares · SCNI
SCNINASDAQotherCurrentCIK 1611747Updated Oct 14, 2026
Name history
BiondVax Pharmaceuticals Ltd. · through Aug 28, 2023
SCNI price & chart
Loading TradingView…
NASDAQ:SCNI on TradingView ↗About the company
We are a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization. We are advancing a pipeline of therapeutic candidates licensed from the Max Planck Society. We also own Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.
In the news
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. News provided by Scinai Immunotherapeutics Ltd. Jun 05, 2025, 09:00 ET Share this article Share to X Share this article Share to X The regulatory approval marks a ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2021 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q1 2023 | Q1 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 25,093,000Source | 11,840,000Source | 14,851,000Source | 19,897,000Source | 24,449,000Source | 88,049,000Source | 23,292,000Source | — | 11,626,000Source | 13,448,000Source | 17,472,000Source | 27,067,000Source |
| Property, Plant and Equipment, NetUSD | — | 8,497,000Source | 10,180,000Source | 10,802,000Source | — | — | 10,817,000Source | — | 7,793,000Source | 9,189,000Source | 10,825,000Source | 11,245,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 989,000Source | 3,076,000Source | 7,506,000Source | 11,285,000Source | — | 10,799,000Source | 15,392,000Source | 1,661,000Source | 1,964,000Source | 4,870,000Source | 14,075,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 139,000Source | 119,000Source | — | — | — | — | — | 73,000Source | 83,000Source | — | — |
| Assets, CurrentUSD | — | 1,506,000Source | 3,657,000Source | 7,770,000Source | — | — | 11,045,000Source | — | 2,054,000Source | 2,391,000Source | 5,447,000Source | 14,370,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | 236,000Source | 324,000Source | 138,000Source | — | — | — | — | 170,000Source | 213,000Source | 437,000Source | 45,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 1,837,000Source | 1,014,000Source | 1,325,000Source | — | — | 1,430,000Source | — | 1,779,000Source | 1,868,000Source | 1,200,000Source | 1,452,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | 5,627,000Source | — | — | — | — | — | — | 5,627,000Source | 5,627,000Source | — | — |
| Additional Paid in CapitalUSD | — | 125,644,000Source | 121,272,000Source | 117,740,000Source | — | — | 116,431,000Source | — | 130,062,000Source | 123,629,000Source | 119,506,000Source | 116,082,000Source |
| Retained Earnings (Accumulated Deficit)USD | — | -121,673,000Source | -126,816,000Source | -123,112,000Source | — | — | -119,350,000Source | — | -125,846,000Source | -117,539,000Source | -122,335,000Source | -115,835,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | -1,740,000Source | -1,740,000Source | -1,740,000Source | — | — | -1,891,000Source | — | -1,740,000Source | -1,740,000Source | -1,740,000Source | -2,007,000Source |
| Stockholders' Equity Attributable to ParentUSD | — | 7,858,000Source | -7,284,000Source | -7,112,000Source | 3,264,000Source | — | -4,810,000Source | -862,000Source | 8,103,000Source | 9,977,000Source | -4,569,000Source | -1,760,000Source |
| Liabilities and EquityUSD | — | 11,840,000Source | 14,851,000Source | 19,897,000Source | — | — | 23,292,000Source | — | 11,626,000Source | 13,448,000Source | 17,472,000Source | 27,067,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | — | 2,120,000Source | 1,672,000Source | 1,888,000Source | — | — | 2,579,000Source | — | 1,585,000Source | 1,806,000Source | 1,780,000Source | 2,338,000Source |
| Operating Lease, Liability, CurrentUSD | — | 497,000Source | 364,000Source | 394,000Source | — | — | — | — | 329,000Source | 424,000Source | 396,000Source | — |
| Operating Lease, Liability, NoncurrentUSD | — | 1,566,000Source | 640,000Source | 927,000Source | — | — | 1,008,000Source | — | 1,644,000Source | 1,402,000Source | 797,000Source | 1,078,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | 441,000Source | 527,000Source | 461,000Source | 756,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | — | — | — | — | — | 90,000Source | 225,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 409,000Source | 284,000Source | 217,000Source | — |
| TradeAndOtherCurrentPayables | —Source | — | — | — | —Source | —Source | — | — | — | — | — | — |
| TradeAndOtherCurrentReceivables | —Source | — | — | — | —Source | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2021 | Q3 2021 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q1 2023 | Q1 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 138,000Source | 134,000Source | 1,421,000Source | 1,649,000Source | 514,000Source | 562,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 252,000Source | 485,000Source | 303,000Source | 682,000Source | 1,139,000Source | 1,602,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | -10,000Source | 83,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,059,000Source | -1,105,000Source | -6,031,000Source | -6,335,000Source | -9,382,000Source | -7,265,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -6,000Source | -521,000Source | -24,000Source | -12,000Source | -637,000Source | -836,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 6,000Source | 521,000Source | 24,000Source | 12,000Source | 637,000Source | 836,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 5,770,000Source | 3,441,000Source | 1,086,000Source | 6,776,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,289,000Source | -1,985,000Source | -284,000Source | -2,915,000Source | -9,205,000Source | -3,302,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,131,000Source | 3,214,000Source | 7,632,000Source | 11,423,000Source | 10,926,000Source | 15,532,000Source | 1,811,000Source | 2,095,000Source | 5,010,000Source | 14,215,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 725,000Source | — | — | 143,000Source | 833,000Source | 916,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -224,000Source | -359,000Source | 1,000Source | -9,000Source | -272,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 252,000Source | 485,000Source | 304,000Source | 682,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | 1,420,000Source | 1,648,000Source | — | 562,000Source |
| General and Administrative ExpenseUSD | — | 6,201,000Source | — | — | 1,141,000Source | 1,289,000Source | 1,191,000Source | 1,452,000Source | — | — | — | 1,502,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 8,130,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | — | -2,983,000Source | -3,515,000Source | -2,475,000Source | -8,307,000Source | 4,796,000Source | -6,500,000Source | -5,796,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | 6,415,000Source | — |
| Nonoperating Income (Expense)USD | — | — | — | — | -1,167,000Source | 280,000Source | -329,000Source | 140,000Source | -765,000Source | -1,325,000Source | — | 5,265,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | 4,890,000Source | 8,058,000Source | 9,706,000Source | — |
| Other Depreciation and AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 514,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -359,000Source | -1,422,000Source | — | 5,100,000Source |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 5,265,000Source |
| Payments for Repurchase of WarrantsUSD | — | — | — | — | — | — | — | — | 59,000Source | 59,000Source | 59,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 2,000,000Source | 139,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | 389Source | — | — |
| Profit or Loss | — | —Source | — | — | — | —Source | — | — | — | — | — | — |
| AdjustmentsForSharebasedPayments | — | —Source | — | — | — | —Source | — | — | — | — | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | — | —Source | — | — | — | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2021 | Q3 2021 | Q2 2023 | Q2 2022 | Q1 2023 | Q1 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | 1,311,000Source | 658,000Source | — | — |
| Cost of Goods and Services Sold | — | — | — | — | — | — | —Source | —Source | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | 2,521,000Source | 2,526,000Source | 4,505,000Source | 5,296,000Source |
| Operating Income (Loss)USD | — | — | — | -3,263,000Source | -3,186,000Source | -2,615,000Source | -7,542,000Source | -8,638,000Source | 9,706,000Source | -11,061,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | -359,000Source | -1,422,000Source | — | 5,100,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | -2,983,000Source | -3,515,000Source | -2,475,000Source | -8,307,000Source | 4,796,000Source | -6,500,000Source | -5,796,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0Source | -0Source | -0Source | -0Source | — | — | -0Source | -0.01Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0Source | -0Source | -0Source | -0Source | — | — | -0Source | -0.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,351,850,046Source | 746,898,671Source | 1,295,256,604Source | 744,711,465Source | 9,339,460,965Source | 3,225,472,266Source | 1,562,627,495Source | 754,076,407Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,351,850,046Source | 746,898,671Source | 1,295,256,604Source | 744,711,465Source | 9,339,460,965Source | 3,225,472,266Source | 1,562,627,495Source | 754,076,407Source |
| Additional Financial Items | ||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 1,421,000Source | 1,649,000Source | — | — |
| General and Administrative ExpenseUSD | — | 6,201,000Source | 1,141,000Source | 1,289,000Source | 1,191,000Source | 1,452,000Source | — | — | — | 1,502,000Source |
| Gross ProfitUSD | — | — | — | — | — | — | -2,652,000Source | -580,000Source | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | 8,130,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | 343,000Source | — |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | 2,968,000Source | — |
| Investment Income, NetUSD | — | — | — | — | — | — | 765,000Source | 1,325,000Source | 3,206,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | 6,415,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -1,167,000Source | 280,000Source | -329,000Source | 140,000Source | -765,000Source | -1,325,000Source | — | 5,265,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | 4,890,000Source | 8,058,000Source | 9,706,000Source | — |
| Other ExpensesUSD | — | — | — | — | — | — | 788,000Source | 1,516,000Source | 941,000Source | — |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | 5,265,000Source |
| Research and Development ExpenseUSD | — | 2,024,000Source | — | 1,974,000Source | 1,995,000Source | 1,163,000Source | 2,369,000Source | 5,532,000Source | 5,210,000Source | 5,765,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | 389Source | — | — |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | — | — | — | — | 8,307,000Source | -4,796,000Source | — | — |
| BasicEarningsLossPerShare | — | —Source | — | —Source | — | — | — | — | — | — |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLoss | — | — | — | —Source | — | — | — | — | — | — |
| DilutedEarningsLossPerShare | — | —Source | — | —Source | — | — | — | — | — | — |
| FinanceCosts | — | —Source | — | —Source | — | — | — | — | — | — |
Offerings
Registration 333-299112
Registration 333-290437
Registration 333-295698
Filing attachments
ea030860501ex4-1.htm · 6-K · 2026-10-15
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗ea030860501ex4-2.htm · 6-K · 2026-10-15
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗ea030860501ex99-1.htm · 6-K · 2026-10-15
Exhibit 99.1 Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement JERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company operating a growing contract development and manufacturing organization (“CDMO”) alongside an immunology-focused therapeutic development platform, today announced that it has entered into a securities purchase agreement with an …
Read attachment ↗ea030843801ex99-1.htm · 6-K · 2026-10-13
Exhibit 99.1 Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025 Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports development activity in 2026 and clinical manufacturing planned for 2027 Potential additional clinical manufacturing carries an indicative, uncommitted service-fee value of $5.85 million for …
Read attachment ↗ea030605801ex99-1.htm · 6-K · 2026-09-21
EX-99.1 2 ea030605801ex99-1.htm PRESS RELEASE DATED SEPTEMBER 21, 2026 Exhibit 99.1 Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, September 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company combining innovative i…
Read attachment ↗ea030483301ex99-1.htm · 6-K · 2026-09-08
Exhibit 99.1 Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALEM, September 8, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company combining innovative …
Read attachment ↗